Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial
Data Show Anti-inflammatory ABX464 inhibits SARS-CoV-2 Viral Replication In Lung
• By Sten Stovall
Abivax says ABX464 has ‘unique’ triple action to treat COVID-19 patients • Source: Shutterstock 
